- Home
- NVCR vs RCKT Comparison
NVCR vs RCKT Comparison
Compare NVCR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | RCKT |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 394.2M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NVCR | RCKT |
|---|---|---|
| Price | $16.28 | $3.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $28.08 | ★ $29.73 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.79 | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $655,353,000.00 | N/A |
| Revenue This Year | $7.72 | N/A |
| Revenue Next Year | $6.74 | $64.28 |
| P/E Ratio | ★ N/A | $5.08 |
| Revenue Growth | ★ 8.28 | N/A |
| 52 Week Low | $9.82 | $2.53 |
| 52 Week High | $21.45 | $5.45 |
Technical Indicators
Market Signals| Indicator | NVCR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 45.31 |
| Support Level | $14.84 | $3.36 |
| Resistance Level | $18.43 | $3.65 |
| Average True Range (ATR) | 0.80 | 0.20 |
| MACD | -0.27 | -0.04 |
| Stochastic Oscillator | 32.09 | 24.33 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.